Real-World Osteoporosis Pharmacotherapy in the UAE: Prescribing Trends, Adherence, and Patient Beliefs

Background: Osteoporosis is a chronic bone disease characterized by reduced bone mass and structural deterioration, increasing fracture risk and affecting patients’ quality of life (QoL). Pharmacological treatments are essential in managing osteoporosis; however, suboptimal prescribing patterns and poor medication adherence can limit therapeutic outcomes. This study primarily aimed to assess medication adherence among patients with osteoporosis using the MMAS-8, as well as prescribing patterns and patient beliefs. Methods: We conducted a single-center cross-sectional observational study at Saqr Hospital, Ras al Khaimah, UAE, between October 2024 and May 2025, enrolling 300 adults with clinically diagnosed osteoporosis and/or a bone mineral density T-score ≤ −2.5. Data were collected through structured interviews and medical-record review. Medication adherence was assessed using the 8-item Morisky Medication Adherence Scale (MMAS-8), and beliefs about medicines were measured using the Beliefs about Medicines Questionnaire (BMQ). Prescribing patterns were characterized by drug class, dose, and frequency, and prescribing appropriateness was evaluated using prescribed daily dose/defined daily dose (PDD/DDD) ratios based on WHO ATC/DDD standards. Predictors of adherence were examined using univariate and multivariable Firth penalized logistic regression. Results: The median age was 70 years (IQR 63–76), 89.0% of participants were female, and 32.0% had a prior fracture history. Denosumab was the most frequently prescribed anti-osteoporotic therapy (59.0%), followed by romosozumab (30.7%), whereas bisphosphonates and parathyroid hormone analogues were infrequently used (2.7% and 4.7%, respectively). Prescribed dosing closely aligned with WHO standards for all evaluated agents. Overall, 40.7% of patients were classified as adherent and 59.3% as non-adherent. Adherence was not significantly associated with age, gender, nationality, fracture history, polypharmacy, or most comorbidities. In contrast, medication beliefs demonstrated a strong relationship with adherence. In multivariable Firth regression, stronger medication concerns were independently associated with lower odds of adherence (adjusted OR 0.033, 95% CI 0.003–0.355; p = 0.0049), while having more than two comorbidities was also associated with reduced adherence (adjusted OR 0.076, 95% CI 0.008–0.688; p = 0.022). Conclusions: In this UAE real-world cohort, osteoporosis pharmacotherapy was dominated by injectable biologic agents and was prescribed in close agreement with standard dosing recommendations. However, medication adherence remained suboptimal. Patient beliefs, particularly treatment-related concerns, emerged as a more important determinant of adherence than demographic or most clinical characteristics. These findings highlight the need for belief-sensitive, patient-centered adherence interventions alongside optimized pharmacotherapy to improve osteoporosis outcomes in routine practice.